This study is in progress, not accepting new patients
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Bristol-Myers Squibb
- Links
- BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls Investigator Inquiry Form
- ID
- NCT04026412
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 888 study participants
- Last Updated